Prolactin-dependent mitogenesis in Nb 2 node lymphoma cells: effects of immunosuppressive cyclopeptides

Insights

Cyclosporine and didemnin B inhibit prolactin-stimulated cell growth by interfering with prolactin receptor interactions. Protein kinase C activation is involved in prolactin-mediated mitogenesis in Nb 2 lymphoma cells.

Area of Science:

  • Cell Biology
  • Endocrinology
  • Pharmacology

Background:

  • Prolactin (PRL) stimulates ornithine decarboxylase (ODC) activity and cell proliferation in Nb 2 node lymphoma cells.
  • Cyclopeptides cyclosporine (CsA) and didemnin B (DB) are known to modulate cellular processes.

Purpose of the Study:

  • To investigate the mechanism by which CsA and DB inhibit PRL-stimulated mitogenesis in Nb 2 cells.
  • To explore the role of protein kinase C (PKC) and other signaling pathways in PRL-mediated cell growth.

Main Methods:

  • Nb 2 node lymphoma cells were treated with PRL, CsA, DB, phorbol ester TPA, calcium ionophore A23187, indomethacin, NDGA, and estradiol-17 beta.
  • PRL binding assays were performed.
  • ODC activity and [3H]thymidine incorporation were measured as indicators of cell proliferation.

Main Results:

  • CsA and DB inhibited PRL-stimulated ODC activity and proliferation, and also inhibited 125I-PRL binding, suggesting interference with PRL receptor interactions.
  • TPA stimulated ODC activity and proliferation, indicating a role for PKC in PRL mitogenesis.
  • A23187 modulated ODC activity and proliferation, suggesting effects on cell cycle progression.
  • Inhibitors of the cyclooxygenase and lipoxygenase pathways affected PRL-stimulated responses.
  • Estrogen alone was not mitogenic but modulated PRL effects.

Conclusions:

  • CsA and DB likely inhibit PRL-dependent responses by interacting with the PRL receptor.
  • PKC activation is a component of the PRL-stimulated mitogenic pathway in Nb 2 cells.
  • Products of the lipoxygenase pathway may contribute to PRL-stimulated mitogenesis.